Yazarlar : Nabhan C, Mehta J.

Yayın : Leuk Lymphoma.

Yayın Yılı : 2012

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22448919

Konu : Kemik İliği Nakli

Literatür İçeriği :  Abstract: While rituximab-based chemoimmunotherapy has improved response and long-term survival rates in diffuse large B-cell non-Hodgkin lymphoma (DLBCL), relapse and death from recurrent disease is still the eventual outcome in a significant proportion of patients; especially those with high-risk disease. Autologous hematopoietic stem cell transplantation (AHSCT) in first remission, which was studied mainly before the advent of rituximab, has lost its appeal due to several small negative trials. However, definitive data do not exist to determine the role of AHSCT in first remission. In this review, we critically evaluate studies investigating AHSCT in DLBCL in first remission. Most available studies have shortcomings that limit the applicability of their findings. AHSCT in first remission may have a role is selected high-risk patients with DLBCL, but a carefully-designed prospective study is required to appropriately evaluate this concept.

Literatür Arşivi